[Preventive medication in migraine headache : Individualized clinical pathways].
With the introduction of the highly effective triptans in the treatment of acute migraine attacks, the significance of migraine prevention temporarily lost ground in the awareness of doctors and, even more so, patients. This was unjustified, as the increasing numbers of patients with triptan-overuse headache clearly demonstrated. Recent years have seen this trend reversed with a resurgence of migraine prevention. In daily practice the first question is whether migraine prevention is indeed indicated for the patient. If answered affirmatively, the next step is the intricate selection of the most promising agent for the patient. Treatment guidelines regularly updated by the relevant medical societies provide a general overview of the agents principally available according to the principles of evidence-based medicine. Yet, low compliance rates suggest that in practice implementation of these guidelines may have to be tailored to the patient in question. The treatment algorithm presented here tries to bridge the gulf between general treatment guidelines and the actual needs of the patient. From this, feasible clinical pathways are derived for individualized treatment.
Heinze
A
A
Neurologisch-verhaltensmedizinische Schmerzklinik Kiel, Heikendorfer Weg 9-27, 24149, Kiel.
Heinze-Kuhn
K
K
Göbel
H
H
D000465:Algorithms; D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use; D002940:Circadian Rhythm; D003131:Combined Modality Therapy; D019091:Critical Pathways; D015444:Exercise; D006261:Headache / Q000139:chemically induced; D006801:Humans; D055118:Medication Adherence; D008784:Methysergide / Q000009:adverse effects / Q000627:therapeutic use; D008881:Migraine Disorders / Q000209:etiology / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use; D012064:Relaxation Therapy; D012307:Risk Factors; D014363:Tryptamines / Q000009:adverse effects / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use
D000700:Analgesics; D011619:Psychotropic Drugs; D014363:Tryptamines; D014662:Vasoconstrictor Agents; D008784:Methysergide